46.59
price down icon1.85%   -0.88
 
loading
전일 마감가:
$47.47
열려 있는:
$46.93
하루 거래량:
2.90M
Relative Volume:
1.11
시가총액:
$112.53B
수익:
$43.23B
순이익/손실:
$6.79B
주가수익비율:
11.63
EPS:
4.0051
순현금흐름:
$9.17B
1주 성능:
-4.98%
1개월 성능:
-1.79%
6개월 성능:
-3.98%
1년 성능:
-8.18%
1일 변동 폭
Value
$46.49
$47.03
1주일 범위
Value
$46.49
$48.90
52주 변동 폭
Value
$44.62
$60.12

사노피 ADR Stock (SNY) Company Profile

Name
명칭
Sanofi Adr
Name
전화
-
Name
주소
-
Name
직원
82,878
Name
트위터
@sanofi
Name
다음 수익 날짜
2025-10-24
Name
최신 SEC 제출 서류
Name
SNY's Discussions on Twitter

SNY을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
SNY
Sanofi Adr
46.59 114.65B 43.23B 6.79B 9.17B 4.0051
Drug Manufacturers - General icon
LLY
Lilly Eli Co
1,038.40 924.53B 59.42B 18.41B 6.44B 20.22
Drug Manufacturers - General icon
JNJ
Johnson Johnson
218.66 529.01B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
214.35 383.08B 59.64B 2.36B 19.68B 1.3253
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
62.33 253.81B 46.69B 15.29B 9.25B 3.4329
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
144.34 274.68B 54.45B 14.42B 17.15B 7.333

사노피 ADR Stock (SNY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2026-01-06 다운그레이드 Barclays Overweight → Equal Weight
2025-12-09 다운그레이드 Guggenheim Buy → Neutral
2025-12-08 다운그레이드 JP Morgan Overweight → Neutral
2025-09-08 업그레이드 Morgan Stanley Equal-Weight → Overweight
2025-09-02 업그레이드 Deutsche Bank Hold → Buy
2025-08-08 업그레이드 JP Morgan Neutral → Overweight
2025-04-15 개시 Exane BNP Paribas Outperform
2025-03-21 개시 Goldman Neutral
2025-01-30 업그레이드 Deutsche Bank Sell → Hold
2024-07-26 재확인 Argus Buy
2024-01-23 개시 Morgan Stanley Equal-Weight
2024-01-16 재개 UBS Buy
2023-12-05 다운그레이드 JP Morgan Overweight → Neutral
2023-10-30 다운그레이드 Stifel Buy → Hold
2023-09-06 업그레이드 Berenberg Hold → Buy
2023-07-14 개시 HSBC Securities Buy
2023-04-28 다운그레이드 Deutsche Bank Hold → Sell
2023-03-27 업그레이드 Barclays Equal Weight → Overweight
2022-12-13 재개 Morgan Stanley Overweight
2022-08-12 업그레이드 Deutsche Bank Sell → Hold
2022-08-09 다운그레이드 UBS Buy → Neutral
2022-05-23 개시 SVB Leerink Outperform
2021-09-27 업그레이드 SVB Leerink Mkt Perform → Outperform
2021-01-15 개시 Deutsche Bank Sell
2020-09-29 개시 Berenberg Hold
2020-03-17 업그레이드 Barclays Underweight → Equal Weight
2020-03-11 업그레이드 Goldman Neutral → Buy
2020-02-11 개시 SVB Leerink Mkt Perform
2020-01-06 업그레이드 JP Morgan Neutral → Overweight
2019-09-23 업그레이드 Guggenheim Neutral → Buy
2019-09-20 업그레이드 Morgan Stanley Equal-Weight → Overweight
2019-09-03 개시 Bernstein Outperform
2019-08-14 업그레이드 UBS Neutral → Buy
2018-12-11 업그레이드 Jefferies Hold → Buy
2018-11-01 업그레이드 Barclays Underweight → Equal Weight
2018-10-09 개시 Guggenheim Neutral
2018-09-10 업그레이드 BofA/Merrill Neutral → Buy
2018-08-10 업그레이드 Citigroup Neutral → Buy
2018-03-23 업그레이드 Liberum Hold → Buy
2018-01-23 다운그레이드 Barclays Equal Weight → Underweight
2017-12-06 다운그레이드 BofA/Merrill Buy → Neutral
2017-12-01 다운그레이드 Morgan Stanley Overweight → Underweight
2017-11-15 업그레이드 Barclays Underweight → Equal Weight
2017-08-30 업그레이드 HSBC Securities Reduce → Hold
모두보기

사노피 ADR 주식(SNY)의 최신 뉴스

pulisher
Jan 16, 2026

Sanofi (SNY) Secures Approval for Cablivi in the US and Plozasiran in China - Finviz

Jan 16, 2026
pulisher
Jan 16, 2026

FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz

Jan 16, 2026
pulisher
Jan 16, 2026

FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (UPDATED) - Benzinga

Jan 16, 2026
pulisher
Jan 15, 2026

Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week? - Finviz

Jan 15, 2026
pulisher
Jan 13, 2026

Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz

Jan 13, 2026
pulisher
Jan 12, 2026

Sanofi (SNY) Reports Regulatory Win, Barclays Downgrades to 'Equal Weight' with EUR 85 PT - Finviz

Jan 12, 2026
pulisher
Jan 09, 2026

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail

Jan 09, 2026
pulisher
Jan 07, 2026

Regeneron Just Moved From Underperform To Buy - Benzinga

Jan 07, 2026
pulisher
Jan 05, 2026

KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - Finviz

Jan 05, 2026
pulisher
Jan 05, 2026

Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz

Jan 05, 2026
pulisher
Jan 05, 2026

FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children - Finviz

Jan 05, 2026
pulisher
Jan 02, 2026

REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Finviz

Jan 02, 2026
pulisher
Dec 31, 2025

Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm

Dec 31, 2025
pulisher
Dec 30, 2025

Jefferies Maintains Buy on Sanofi (SNY) Despite Regulatory Overhang - Finviz

Dec 30, 2025
pulisher
Dec 30, 2025

Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies CorporationDVAX - Sahm

Dec 30, 2025
pulisher
Dec 30, 2025

Where is Sanofi (SNY) Headed According to Wall Street? - Finviz

Dec 30, 2025
pulisher
Dec 29, 2025

Delayed MS Decision and Trial Miss Add to Sanofi's R&D Challenges - Finviz

Dec 29, 2025
pulisher
Dec 28, 2025

Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX) - Finviz

Dec 28, 2025
pulisher
Dec 25, 2025

Total debt per share of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView — Track All Markets

Dec 25, 2025
pulisher
Dec 24, 2025

Why Dynavax Stock Soared Today - Finviz

Dec 24, 2025
pulisher
Dec 24, 2025

Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise - Finviz

Dec 24, 2025
pulisher
Dec 24, 2025

Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy - Sahm

Dec 24, 2025
pulisher
Dec 24, 2025

Our Environmental Impact - Sanofi

Dec 24, 2025
pulisher
Dec 21, 2025

Bloom Energy Aktie: KI-Boom trifft auf Energiekrise! - Finanztrends

Dec 21, 2025
pulisher
Dec 17, 2025

Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades - Finviz

Dec 17, 2025
pulisher
Dec 16, 2025

FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz

Dec 16, 2025
pulisher
Dec 15, 2025

Sanofi (SNY) sees slight pessimism from analysts - MSN

Dec 15, 2025
pulisher
Dec 15, 2025

Sanofi: Today's Tolebrutinib Setback Shouldn't Worry ShareholdersThis Is Why (SNY) - Seeking Alpha

Dec 15, 2025
pulisher
Dec 15, 2025

Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration - Sahm

Dec 15, 2025
pulisher
Dec 15, 2025

Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks - Sahm

Dec 15, 2025
pulisher
Dec 15, 2025

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025) - ts2.tech

Dec 15, 2025
pulisher
Dec 14, 2025

SNY Stock Price and Chart — NASDAQ:SNY - TradingView — Track All Markets

Dec 14, 2025
pulisher
Dec 12, 2025

Sanofi (SNY) Sees Slight Pessimism From Analysts - Finviz

Dec 12, 2025
pulisher
Dec 10, 2025

JPMorgan Downgrades Sanofi (SNY) to EUR 95 from EUR 105 - Finviz

Dec 10, 2025
pulisher
Dec 10, 2025

TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia - Finviz

Dec 10, 2025
pulisher
Dec 10, 2025

Why Wall Street Analysts Are Closely Watching Sanofi (SNY) - Finviz

Dec 10, 2025
pulisher
Dec 09, 2025

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play - Finviz

Dec 09, 2025
pulisher
Dec 09, 2025

KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study - Finviz

Dec 09, 2025
pulisher
Dec 09, 2025

Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks - Sahm

Dec 09, 2025

사노피 ADR (SNY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general PFE
$25.65
price down icon 0.93%
$124.91
price up icon 3.01%
$330.41
price up icon 0.12%
drug_manufacturers_general MRK
$108.83
price down icon 1.93%
drug_manufacturers_general NVS
$144.34
price up icon 0.83%
자본화:     |  볼륨(24시간):